Ligand Pharmaceuticals (LGND) Non Operating Income (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Non Operating Income data on file, last reported at -$41.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 198.1% year-over-year to -$41.6 million; the trailing twelve-month figure through Mar 2026 stood at $90.3 million (up 190.93% YoY), and the FY2025 full-year result was $118.0 million, up 369.5% from the prior year.
• Non Operating Income fell to -$41.6 million in Q1 2026, from $42.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $110.5 million in Q1 2024 to a low of -$46.3 million in Q2 2024.
• A 5-year average of $10.9 million and a median of $13000.0 in 2022 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 515500.0% in 2023, while the deepest fall reached 117192.31% in 2023.
• Tracing LGND's Non Operating Income over 5 years: stood at $44.2 million in 2022, then tumbled by 53.76% to $20.5 million in 2023, then slumped by 244.53% to -$29.6 million in 2024, then soared by 245.24% to $42.9 million in 2025, then tumbled by 196.95% to -$41.6 million in 2026.
• Business Quant data shows LGND's Non Operating Income at -$41.6 million in Q1 2026, $42.9 million in Q4 2025, and $86.2 million in Q3 2025.